• Re: 'ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies' by Mikulska et al.
  Wijetilleka S, Jayne D, Mukhtyar C, Karim MY. Clin Microbiol Infect 2019;25:531-532. doi: 10.1016/j.cmi.2018.12.025.

• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus
  document on the safety of targeted and biologic therapies: an infectious diseases
  perspective—cell surface receptors and associated signaling pathways.
  Aguilar-Company J, Fernández-Ruiz M, García-Campelo R, Garrido-Castro AC, Ruiz-Camps I. Clin Microbiol Infect 2018;24:S41-S52. doi: 10.1016/j.cmi.2017.12.027.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22,
  CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).
  Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. Clin Microbiol Infect 2018;24:S83-S94. doi: 10.1016/j.cmi.2018.03.022.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
  Baddley JW, Cantini F, Goletti D, et al. Clin Microbiol Infect 2018;24:S10-S20. doi: 10.1016/j.cmi.2017.12.025
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
  Reinwald M, Silva JT, Mueller NJ, et al. Clin Microbiol Infect 2018;24:S53-S70. doi: 10.1016/j.cmi.2018.02.009
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and
  CD52).
  Mikulska M, Lanini S, Gudiol C, et al. Clin Microbiol Infect 2018;24:S71-S82. doi: 10.1016/j.cmi.2018.02.003.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Soluble immune effector molecules [II]: agents targeting interleukins,
  immunoglobulins and complement factors).
  Winthrop KL, Mariette X, Silva JT, et al. Clin Microbiol Infect 2018;24:S21-S40. doi: 10.1016/j.cmi.2018.02.002.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-
  phosphate receptor modulators and proteasome inhibitors).
  Redelman-Sidi G, Michielin O, Cervera C, et al. Clin Microbiol Infect 2018;24:S95-S107. doi: 10.1016/j.cmi.2018.01.030.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Introduction).
  Fernández-Ruiz M, Meije Y, Manuel O,et al. Clin Microbiol Infect 2018;24:S2-S9. doi: 10.1016/j.cmi.2018.01.029
• Editorial for ESCMID Study Group for Infections in Compromised Hosts (ESGICH)
  Consensus Document on the safety of targeted and biological therapies:
  an infectious diseases perspective.
  Aguado JM, Manuel O. Clin Microbiol Infect 2018;24 S1. doi: 10.1016/j.cmi.2018.04.029.
• Re: "Comparison of antipseudomonal betalactams for febrile neutropenia empiric
  therapy: systematic review and network metaanalysis" by Horita et al.
  Averbuch D, Orasch C, Mikulska M, et al. Clin Microbiol Infect 2018;24:662-663. doi: 10.1016/j.cmi.2018.01.012.
• Recommendations for Management of Endemic Diseases and Travel Medicine in
  Solid-Organ Transplant Recipients and Donors: Latin America.
  Clemente WT, Pierrotti LC, Abdala E, et al. Transplantation 2018;102:193-208. doi: 10.1097/TP.0000000000002027.

ESGICH, ESGCIP and EPASG

• The role of infection models and PK/PD modelling for optimising care of critically ill
  patients with severe infections. Tängdén T, Ramos Martín V, Felton TW, Nielsen E, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases. Intensive Care Med. 2017 Jul;43(7):1021-1032. 

• Risk Factors Associated With Early Invasive Pulmonary Aspergillosis in Kidney
  Transplant Recipients: Results From a Multinational Matched Case-Control Study. López-Medrano F, Silva JT1, Fernández-Ruiz M, Carver PL, van Delden C, Merino E, Pérez-Saez MJ, Montero M, Coussement J, de Abreu Mazzolin M, Cervera C, Santos L, Sabé N, Scemla A, Cordero E, Cruzado-Vega L, Martín-Moreno PL, Len Ó, Rudas E, de León AP, Arriola M, Lauzurica R, David M, González-Rico C, Henríquez-Palop F, Fortún J, Nucci M, Manuel O, Paño-Pardo JR, Montejo M, Muñoz P, Sánchez-Sobrino B, Mazuecos A, Pascual J, Horcajada JP, Lecompte T, Lumbreras C, Moreno A, Carratalà J, Blanes M, Hernández D, Hernández-Méndez EA, Fariñas MC, Perelló-Carrascosa M, Morales JM, Andrés A, Aguado JM1; Spanish Network for Research in Infectious Diseases (REIPI), the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), the Study Group for Infections in Compromised Hosts (ESGICH) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Swiss Transplant Cohort Study (STCS). Am J Transplant. 2016;16(7):2148-57.
• Clinical Presentation and Determinants of Mortality of Invasive Pulmonary
  Aspergillosis in Kidney Transplant Recipients: A Multinational Cohort Study. López-Medrano F, Fernández-Ruiz M, Silva JT, Carver PL, van Delden C, Merino E, Pérez-Saez MJ, Montero M, Coussement J, de Abreu Mazzolin M, Cervera C, Santos L, Sabé N, Scemla A, Cordero E, Cruzado-Vega L, Martín-Moreno PL, Len Ó, Rudas E, de León AP, Arriola M, Lauzurica R, David M, González-Rico C, Henríquez-Palop F, Fortún J, Nucci M, Manuel O, Paño-Pardo JR, Montejo M, Muñoz P, Sánchez-Sobrino B, Mazuecos A, Pascual J, Horcajada JP, Lecompte T, Moreno A, Carratalà J, Blanes M, Hernández D, Fariñas MC, Andrés A, Aguado JM; Spanish Network for Research in Infectious Diseases (REIPI), the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), the Study Group for Infections in Compromised Hosts (ESGICH) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Swiss Transplant Cohort Study (STCS). Am J Transplant. 2016;16(11):3220-3234.